MicroCHIPS, an MIT-affiliated developer of implantable drug delivery devices and biosensors, found their programmable implant was able to deliver the osteoporosis drug teriparatide at scheduled intervals and was well tolerated by patients, according to a news release.
For the study, seven osteoporotic postmenopausal patients aged 65-70 received the microchip-based implant. Researchers found the drug and device combination was biocompatible, and patients reported no adverse side effects. The company plans to file for regulatory approval for its first microchip device in 2014.
Related Articles on Medical Devices:
Negotiations Over Medical Device Fees Continue in Congressional Hearing
GHX to Create Industry's First Implantable Devices Supply Chain Solution for Physician Preference Items
Study: CMS Has Incorporated Evidence-Based Medicine Into Medical Technology Decisions
For the study, seven osteoporotic postmenopausal patients aged 65-70 received the microchip-based implant. Researchers found the drug and device combination was biocompatible, and patients reported no adverse side effects. The company plans to file for regulatory approval for its first microchip device in 2014.
Related Articles on Medical Devices:
Negotiations Over Medical Device Fees Continue in Congressional Hearing
GHX to Create Industry's First Implantable Devices Supply Chain Solution for Physician Preference Items
Study: CMS Has Incorporated Evidence-Based Medicine Into Medical Technology Decisions